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Poznan University of Medical
Sciences, Poland
Reviewed by:
Amanda Psyrri,
University General Hospital Attikon,
Greece
Lukasz Bialkowski,
National Cancer Institute (NCI),
United States
*Correspondence:
Ramez Philips
ramez.philips@jefferson.edu
Specialty section:
This article was submitted to
Head and Neck Cancer,
a section of the journal
Frontiers in Oncology
Received: 17 March 2021
Accepted: 07 June 2021
Published: 01 July 2021
Citation:
Philips R, Han C, Swendseid B,
Curry J, Argiris A, Luginbuhl A
and Johnson J (2021) Preoperative
Immunotherapy in the Multidisciplinary
Management of Oral Cavity Cancer.
Front. Oncol. 11:682075.
doi: 10.3389/fonc.2021.682075

Frontiers in Oncology | www.frontiersin.org

Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, PA, United States,
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States

Despite advances in multimodal treatment for oral cavity squamous cell carcinoma,
recurrence rates remain high, providing an opportunity for new therapeutic modalities
that may improve oncologic outcomes. Much recent attention has been paid to the
molecular interactions between the tumor cells with the adjacent peritumoral
microenvironment, in which immunosuppressive molecular changes create a landscape
that promotes tumor progression. The rationale for the introduction of immunotherapy is
to reverse the balance of these immune interactions in a way that utilizes the host immune
system to attack tumor cells. In the preoperative setting, immunotherapy has the
advantage of priming the unresected tumor and the associated native immune
inﬁltration, supercharging the adaptive anti-tumor immune response. It also provides
the basis for scientiﬁc discovery where the molecular proﬁle of responders can be
interrogated to elucidate prognostic markers to aid in future patient selection.
Preoperative immunotherapy is not without limitations. The risk of surgical delay due to
immune adverse events must be carefully discussed by members of a multidisciplinary
treatment team and patient selection will be critical. One day, the discovery of predictive
biomarkers may allow for algorithms where pre-surgical immunotherapy decreases the
size of surgical defect and impacts the intensity of adjuvant therapy leading to improved
patient survival and decreased morbidity. With further study, immunotherapy could
become a key component of future treatment algorithm.
Keywords: immunotherapy, oral cavity squamous cell carcinoma (OCSCC), preoperative, multidisciplinary (care or
team), multimodality, head and neck squamouscell carcinoma (HNSCC), induction, window of opportunity

INTRODUCTION
Oral cavity squamous cell carcinoma (OCSCC) affects approximately 34,000 people in the United
Stated every year (1). The treatment of OCSCC often requires a multimodality approach involving
surgery, radiation, and chemotherapy. The standard of care for locally advanced OCSCC is surgery
followed by adjuvant radiation or chemoradiation based on adverse pathologic features of the
primary tumor and involved cervical lymph nodes. Nonsurgical management is usually reserved for
unresectable or inoperable tumors (2, 3). Therapeutic decisions incorporate patients’ oncological,
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have failed to show improvement in locoregional relapse, disease-free
survival, and overall survival in OCSCC (9–13). A randomized trial
compared the impact of induction chemotherapy with 3 cycles of
cisplatin and ﬂuorouracil followed by surgery (n=99) versus upfront
surgery (n=99) in stage T2-T4, N0-N2, previously untreated patients
(13). After a median follow up of 11.5 months, there was no
difference in overall survival, locoregional relapse, and distant
metastasis between the two groups (p = 0.340; p = 0.634; p =
0.153, respectively). Another phase 3 trial, published by Zhong et al.
compared induction chemotherapy with 2 cycles of docetaxel,
cisplatin, and ﬂuorouracil (TPF) followed by surgery (n=128)
versus upfront surgery (n=128) in patients with stage III/IVa
locally advanced resectable OCSCC. Similarly, there was no
signiﬁcant difference in overall survival (p = 0.918) or disease-free
survival (p = 0.897) between patients receiving induction
chemotherapy versus upfront surgery. A meta-analysis of the
previous two studies conﬁrmed lack of difference in locoregional
recurrence, overall, and disease-free survival between patients
receiving induction chemotherapy versus upfront surgery (9).
Further subgroup analysis of individual data from cN2 patients
showed statistically signiﬁcant overall survival beneﬁt in favor of
induction chemotherapy. Furthermore, studies have shown a high
toxicity proﬁle related to induction chemotherapy (11, 13). Rates of
grade 3/4 adverse events in the above cited clinical trials ranged from
6.6 to 37% with 3 associated fatalities (3%) reported in the Bossi et al.
clinical trial (11–13).
Induction chemotherapy’s toxicity proﬁle combined with lack
of demonstrable oncologic improvement has resulted in this
strategy falling out of favor in the treatment of OCSCC.
Nevertheless, the rationale and need for preoperative systemic
treatment still holds and immunotherapy offers an enticing
alternative for preoperative treatment.

functional, medical, and quality of life needs. Individualized
treatment requires multidisciplinary management by a team
that includes a head and neck surgeon, medical oncologist,
radiation oncologist, speech therapist, nutritionist, and social
worker to address patient-speciﬁc needs. Despite advancement in
treatment modalities and multidisciplinary approaches,
recurrence in advanced OCSCC remains elevated, with a 5070% 5-year disease-free survival rate, providing an opportunity
to incorporate novel therapeutic options that have potential to
improve oncologic outcomes (4–7).
The value of immunotherapy in recurrent/metastatic head
and neck squamous cell carcinoma (HNSCC) has been supported
by multiple clinical trials (8). Immunotherapy enhances survival
with fewer signiﬁcant side-effects when compared to chemotherapy
in this setting. Given these encouraging results in recurrent and
metastatic disease, the role of immunotherapy is being evaluated in
locally advanced OCSCC. Immunotherapy has particular appeal in
the preoperative setting, as it can supercharge the native immune
inﬁltrate within the peritumoral microenvironment, creating a
powerful antitumoral response that can last beyond surgery and
decrease the risk of local, regional, and metastatic recurrence.
Although the introduction of preoperative immunotherapy in
OCSCC management has exciting implications, it comes with its
own challenges as we continue to understand its role in
multidisciplinary treatment.
In this review, we discuss preoperative treatment in OCSCC, the
rationale for using immunotherapy speciﬁcally in the preoperative
setting, and the limitations of this treatment. We ﬁnally summarize
clinical trials involving preoperative immunotherapy and discuss
its potential role in multidisciplinary management.

PREOPERATIVE THERAPIES IN OCSCC
Preoperative therapeutic modalities in OCSCC include window
of opportunity trials (WOTs), induction therapy and neoadjuvant
therapy. WOTs in the preoperative setting are designed with the
purpose of scientiﬁc discovery rather than pure therapeutic intent.
In WOTs, a biopsy is ﬁrst performed, followed by administration
of an investigational drug during a window of time before surgery.
Then, after surgical resection, the ﬁnal pathologic specimen is
compared to the biopsy tissue taken before the experimental drug
was administered. This allows for assessment of the degree of
tumor response, identiﬁcation of pertinent prognostic biomarkers
comparison of tumor and peritumoral microenvironmental
characteristics between the pretreatment and posttreatment
specimens. Oral cavity cancer is usually easily amenable to
biopsy and provides a good model for WOT.
Preoperative treatment involves administering chemotherapy
to shrink the tumor before deﬁnitive treatment with either
surgery, radiation or chemoradiation. This technique has
garnered interest in the management of OCSCC related to
desire to control micrometastasis and the desire to convert
borderline unresectable tumor to resectable tumors. Unfortunately,
phase III randomized trials and meta-analyses evaluating use of
induction chemotherapy followed by surgery versus upfront surgery
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IMMUNE RESPONSE IN OCSCC
To understand the rationale for immunotherapy in HNSCC and
more speciﬁcally OCSCC, an evaluation of the immune system
and how it interacts with the tumor is essential. The initial tumor
response is non-speciﬁc and is characterized by the innate
immune system consisting of dendritic cells, macrophages, and
natural killer cells. The adaptive immune response, characterized
by lymphocytes, is subsequently activated by the presentation of
tumor neoantigens via major histocompatibility complex (MHC)
proteins to T cells. Tumor cells and antigen presenting cells
(APCs) signal immature T cells leading to their activation and
subsequent modulation (Figure 1). In the ﬁrst signal the human
leukocyte antigen (HLA) complex interacts with the T cell
leading to their proliferation. A second signal via CD80/CD28
molecules leads to activation of T cells into tumor speciﬁc
cytotoxic CD8+ T cells or helper CD4+ T cells. These activated
T cells can further be modulated by costimulatory or inhibitory
molecules. Costimulatory molecules can lead to maintenance of
activation while inhibitory checkpoints lead to anergy/senescence
or apoptosis of T cells. In concert, these signals create a nuanced
response by the immune system to tumoral neoantigens.

2

July 2021 | Volume 11 | Article 682075

Philips et al.

Preoperative Immunotherapy in OCSCC

A

B

FIGURE 1 | Tumor cells and antigen presenting cells (APCs) interact with immature T cells in a series of signals leading to their activation and subsequent modulation.

checkpoint inhibitors play a role in tightly regulating immune
activation to prevent autoimmunity and prolonged inﬂammatory
states (15). Two prominent immune checkpoints receptors include
programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen4 (CTLA-4). PD-1 is expressed in effector and regulatory T-cells
and interacts with two ligands: PD-L1 and PD-L2. The interaction
between PD-1 and PD-L1/2 induces T cell exhaustion, down
regulation, and subsequent adaptive immune tolerance (15, 19).
Therefore, high tumor expression of PD-L1 can lead to tumor
evasion. In keeping with this theory, PD-L1 is expressed in up to
83% of OCSCC (15–17, 20, 21). Anti-PD1/PD-L1 agents boost the
antitumor response by inhibiting the immunosuppressive
signaling of these immune checkpoint signals (16).
Pembrolizumab and nivolumab, IgG4 monoclonal antibodies
that target PD-1, are currently approved for recurrent/metastatic
HNSCC based on well documented efﬁcacy in clinical trials (22,
23). The success of these compounds in recurrent/metastatic
HNSCC provides a rationale for their introduction in
preoperative treatment in OCSCC.
Similarly, CTLA-4 is expressed on T cells and interacts with
the CD80/CD86 on antigen presenting cells (APCs) by
competing with its stimulatory counterpart CD28 to primarily
inhibit differentiation of naïve T-cells (24). CTLA-4 is

HNSCCs evade their host immune response mechanisms
through various molecular-level techniques (14). These techniques
can be categorized into factors related to 1) the tumor (HLA
mutations, cytokine release, checkpoint inhibition, costimulatory
molecules) and 2) the tumor microenvironment (Table 1).
OCSCC has a high mutational burden related to the DNA
damage caused by smoking and alcohol. Thus, tumor
progression in the face of an intact immune system relies on
natural selection of mutations that aid in immune system
evasion. Particularly, mutations in the HLA and antigen
processing machinery (APM) in OCSCC are important in
escaping the immune system (15, 16). As described above, the
HLA/APM complex is the ﬁrst signal in activating T cells for
eradication of tumor cells (17). Importantly, a complete loss of
HLA/APM complex is a stimulator for NK cells to target and
eradicate tumor cells (18).Therefore, to evade the immune
system successfully, a mutation of the HLA/APM complex
needs to alter protein structure and expression without causing
complete loss of function. This alteration compromises the ﬁrst
signal of T cell activation and dampens the adaptive immune
response aiding in tumor progression.
As highlighted above, inhibitory molecules can induce the
adaptive immune response into a state of senescence. Immune

TABLE 1 | Methods of immune evasion.
Tumor related factors

Tumor microenvironment

MHC/APM mutations
Immunosuppressive cytokine release (TGF-b, IL-6, IL-10)
Upregulating (checkpoint) inhibitor molecules
Downregulating costimulatory molecules

Myeloid-derived suppressor cells (MDSCs)
Regulatory T cells (Tregs)
Tumor-associated macrophages (TAMs)
Cancer-associated ﬁbroblasts (CAFs)

MHC, major histocompatibility complex; APM, antigen presenting machinery.
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understandably reduced via tumoral mechanisms in OCSCC.
A well-studied, downregulated cytokine is IL-2, which normally
promotes innate and adaptive immune system activation. To
address this deﬁciency, IRX-2, a homologous cell-derived
complex multi-cytokine biologic preparation, consisting of
active IL-2, IL-1b, gamma interferon (IFNg), and tumor
necrosis factor-a (TNF-a), is being studied in phase I/IIa trials
in OCSCC and has shown promise (42–44). IRX-2 acts on T cells
by preventing tumor-induced apoptosis and enhances its effector
function, particularly in regional lymph nodes, to reinvigorate
both innate and adaptive host immunity in the battle against
tumor cells (44). A phase IIb trial (NCT02609386) in which 97
patients with stage II-IV OCSCC received perilymphatic
injection of IRX-2 recently demonstrated a signiﬁcant increase
in immune response, particularly cytotoxic CD8+ T cells (45)..
Its immune restorative effect on regional lymph nodes is
particularly attractive in combination with other checkpoint
inhibitors. The trial remains active and is pending ﬁnal
endpoint results on event-free and overall survival.
As highlighted above, tumor cells have evolved to alter their
own immunogenicity through selected mutations and
production of immunomodulatory mediators. These
mechanisms occur in the context of a tumor microenvironment
which contains a variety of immunomodulatory cells.
Immunomodulatory cells create an immunosuppressed
environment permissive of tumor progression. Such cells include
regulatory T cells (Tregs), myeloid-derived suppressor cells
(MDSCs), tumor-associated macrophages (TAMs), and cancerassociated ﬁbroblasts (CAFs) (15). These cells express
immunosuppressive cytokines, immune checkpoint inhibitors,
and work in concert to create a microenvironment that silences
the immune system and permits tumor growth (39, 46–53).
Targeting of these immunomodulatory cells can alter the tumor
microenvironment and promote an immune anti-tumor response.
Tregs express previously discussed immunosuppressive cytokines
such as TGF-b and IL-10, which function to undermine T cell
function (39). Monoclonal antibodies against receptors on Tregs
have been developed to deplete levels of Tregs in the tumor
microenvironment; one example is Mogamulizab, a monoclonal
antibody which targets CCR4 on Tregs, showed promising results
in lung/esophageal cancer patients and is currently being
investigated in HNSCC (54). Another method of targeting
immunomodulatory cells, particularly MDSCs and TAMs,
includes cell differentiation into an alternative phenotype.
MDSCs are immature myeloid-derived cells that play a role in T
cell suppression. Targeting MDSCs for the differentiation into
their mature phenotype can inhibit their immunosuppressive
nature (55). TAMs consist of M1 and M2 TAMs that represent
opposing roles in immunomodulation. M2 TAMs are associated
with oncogenic properties. In contrast, M1 TAMs are associated
with tumor suppressive properties. The peritumoral
microenvironment around OCSCC commonly shows an
oncogenic increased ratio of M2: M1 TAMs, providing an
opportunity to target M2 TAMs and alter the M2:M1 ratio
towards a more tumor-suppressive phenotype (56, 57). Finally,
an alternative strategy involves targeting chemotactic receptors in

upregulated in OCSCC and plays an important role in immune
evasion (25). Inhibition of CTLA-4 can lead to inﬁltration of the
tumor microenvironment with T cells and increases antitumor
response (26). Multiple monoclonal antibodies against CTLA-4
have been developed to take advantage of this mechanism;
ipilimumab was the ﬁrst immune checkpoint inhibitor to be
approved by the Food and Drug Administration (FDA) for the
treatment of metastatic melanoma (27). Unlike PD-1 inhibitors,
CTLA-4 inhibitors are not approved for use in HNSCC at this
time, although multiple trials are currently underway. CTLA4directed agents may have a role to play in the future for OCSCC
based upon these results.
Other important novel immune checkpoints include
lymphocyte activation gene-3 (LAG-3), T-cell immunoglobulin
and mucin containing protein-3 (TIM-3), and B7 Homolog 3
(B7-H3) (28, 29). LAG-3 is expressed on exhausted T cells and
interacts with tumor cells to inhibit cytotoxic T cell signaling.
Inhibition of LAG-3 can lead to recruitment of cytotoxic CD8+ T
cells and has shown to restrain tumor growth in in vivo models
(28). Current clinical trials are investigating the role of antiLAG-3 antibody (BMS-986016) with and without anti-PD1 in
solid tumors including HNSCC (NCT01968109). Similarly,
TIM-3 is expressed on lymphocytes and can lead to negative
regulation of T helper cells and exhaustion of cytotoxic CD8+ T
cells in HNSCC (29). In vivo models have shown that anti-TIM-3
therapy leads to tumor suppression. Anti-TIM-3 therapies are
also being investigated in advanced solid tumors, but their
speciﬁc role in HNSCC has not been elucidated. Finally, B7H3 is one of the newest modulators of T-cell response and is
expressed in head and neck cancer. This molecule has a costimulatory role and is thought to be utilized by cancers to evade
immune activation (30). Phase 2 clinical trials are investigating
the role of anti-B7-H3 molecules in HNSCC (NCT04634825).
Another tumor-related mechanism involves the suppression
of immune costimulatory pathways, which would normally
promote immune activation. A prominent molecule in the
costimulatory pathway includes OX40, which is expressed on T
cells and leads to their proliferation (15, 31). OX40 requires
interaction with its ligand to induce antitumor immune activity.
In HNSCC, the OX40 ligand is reduced on the tumor itself
leading to suppression of immune activation, despite OX40
overexpression on host T cells (32, 33) (34). CD137, another
costimulatory molecule, is expressed on cells of the adaptive
immune system (T cells, NK cells) and promotes a healthy
immune response (35). As such, agonistic CD137 therapy has
shown to reduce tumor growth in a OCSCC mouse model (36).
Additionally, the combination of costimulatory molecule
agonists and check point inhibitor antagonists is being
investigated in clinical trials (37).
Tumor cells have also evolved to produce cytokines to silence
the adaptive immune response and lead to tumor cell
progression. Particularly, OCSCC cells secrete inﬂammatory
immune suppressive cytokines such as transforming growth
factor (TGF)-b, interleukin (IL)-6, and IL-10 (38). These
cytokines alter T cell signaling, subsequently suppressing their
effector function (39–41). Immune activating cytokines are
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complexity of the tumor immune landscape and its implication
on treatment response and prognosis (60, 62).
Providing preoperative immunotherapy in WOT allows for
assessment of pathologic response. Proﬁles of responders can be
compiled from the pretreatment specimens and interrogation of
the posttreatment samples can allow for mechanistic and
prognostic insights (63). Although WOT are not designed for
justiﬁcation to change standard of care, they can provide the pilot
data for further trials and relatively short turn around on their
correlative primary endpoints. The discovery of prognostic
biologic markers can lead to individualized patient-centered
treatment based on the patient’s unique immune proﬁle.
Currently, there are no validated tumor signature markers that
can accurately predict response (64, 65). A list of tumor
biomarkers being studied in preoperative immunotherapy
clinical trials is listed in Table 2.

TAMs and MDSCs to prevent their recruitment in the tumor
microenvironment and suppress tumor growth.

RATIONALE FOR PREOPERATIVE
IMMUNOTHERAPY IN OCSCC
As highlighted above, OCSCC has evolved molecular
mechanisms to escape the host immune system and alter the
peritumoral microenvironment to provide ripe conditions for
tumor progression. These molecular changes provide the basis for
exploring how immunotherapy might ﬁt into the treatment
algorithm for OCSCC. In the following section, we address the
rationale for immunotherapy particularly in the preoperative setting.

Clinical Advantages
The high recurrence rate in patients with OCSCC can be attributed
to the presence of micrometastasis beyond the surgical ﬁeld. Early
systemic immunotherapy may enhance the eradication of
micrometastatic deposits that lie outside of the planned surgical
ﬁeld, with potential to decrease rates of local, regional, or metastatic
recurrence Although this advantage is present in any preoperative
systemic therapy, preoperative immunotherapy has the advantage
of a more tolerable side effect proﬁle than that of traditional
cytotoxic induction chemotherapy as discussed above. Patients
who are treated with immune checkpoint inhibitors may
therefore be more likely to tolerate subsequent aspects of their
multidisciplinary care. The application of immunotherapy in the
pre-operative setting rather than post-operatively or in the
recurrent/metastatic setting also provides the distinct advantage of
an intact tumor bed (Figure 2). As discussed above, the ability to
effectively reinstate an adaptive immune response is based on
presence of neoantigens and subsequent activation of T cells. In
an unresected/unmanipulated tumor bed, there is an abundance of
neoantigens (58). In the setting of preoperative immunotherapy, the
presence of diverse numerous neoantigens can lead to polyclonal
activation of mature T cells and subsequent activation of a strong
adaptive immune response, which can have lasting effects beyond
surgery (58, 59). Thus, the addition of preoperative immunotherapy
to the current standard of treatment illustrates a method of
treatment intensiﬁcation in a cancer that has been proven difﬁcult
to cure. At the same time, however, for those patients who respond
robustly to preoperative treatment, less morbid surgical approaches
may also become an option.

LIMITATIONS OF PREOPERATIVE
IMMUNOTHERAPY TREATMENT
Although the implications of immunotherapy in treatment of
OCSCC are enticing, limitations should not be understated.
While the side effect proﬁle of immunotherapy is considered to
be more tolerable than that of cytotoxic treatment, grade 3 and
higher events have been reported in HNSCC (23, 42). Recently
published trials have shown a low toxicity proﬁle of monotherapy
with immune checkpoint inhibitors in the preoperative setting,
though grade 3/4 events can still occur, causing signiﬁcant
morbidity to individual patients (61).Trials highlighting the
success of combination checkpoint immunotherapy or
combination immunotherapy/chemotherapy have also
established the increased toxicity related to targeting multiple
pathways in the immune system (66, 73). Such side effects are
sometimes subject to a variable length of treatment for full
recovery (23, 74–76). Although very infrequent, adverse events
can theoretically have implications on delay in surgical treatment
and a detrimental effect on oncologic outcomes for individual
patients (8). Besides the oncologic implications, complications can
cause long-lasting comorbidities that require prolonged
management beyond the period of cancer treatment (66). As
such, preoperative immunotherapy must demonstrate oncologic
beneﬁt to justify the increase in patient morbidity in order to
receive widespread acceptance.
In addition to the systemic side effects of immunotherapy, it is
possible that immunotherapy could cause local treatment effect
related to the recruitment of cells of the adaptive immune system
and resultant debris. This can lead to issues with wound healing
and subsequent surgical complications. A multi-institutional case
series by Mays et al. aimed to elucidate the relationship between
immunotherapy and surgical wound complications in patients
undergoing ablative and ﬂap reconstructive surgery. The results
indicate an association between preoperative immunotherapy and
major complications requiring invasive surgical treatment (OR
3.7; p = 0.048) and any type of treatment for complications in
patients receiving preoperative immunotherapy (OR 2.9; p =

Biomarker Discovery
In addition to the clinical advantages listed above, pre-operative
immunotherapy trials can provide a research mechanism for
biomarker discovery. A phenomenon noted in the use of
immunotherapy is the inter- and intra-tumor heterogeneity in
response to immunotherapy (60). Clinical trials have shown that
the range of pathologic response to immunotherapy is wide and
correlates with recurrence rates between patients (61).
Interestingly, studies have shown that even within the same
patient, immunotherapy can have a different effect on the
primary tumor bed and regional metastasis, highlighting the
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FIGURE 2 | An unresected tumor bed provides diverse neoantigens, which leads to polyclonal activation of mature T cells and subsequent activation of a strong
adaptive immune response. Created with BioRender.com.

patient after receiving preoperative nivolumab prior to deﬁnitive
surgery (62). This study identiﬁed a discordance rate of 50%
between lymph node metastasis and primary tumor. Further
analysis revealed that treatment discordance correlates with
differences in local immune cell make up. This study highlights
the challenges associated with a highly heterogenous disease.
Finally, a limitation of preoperative immunotherapy is the
phenomenon of observed tumor growth noted by clinical or
radiologic exam after initial treatment (78). When tumor
enlargement is noted after immunotherapy, a distinction
between true progression and pseudoprogression is required.
True progression refers to an actual increase in tumor size after
treatment. In contrast, pseudoprogression refers to a radiologic
increase in tumor size after treatment and is related to
inﬂammatory recruitment and necrosis as opposed to actual

0.008) (77). Although there are inherent limitations in a
retrospective case series with no true matched case-controls, the
study ﬁndings highlight a need to assess the timing of
immunotherapy in the preoperative period so as to limit
potential surgical morbidity due to prior treatment.
The variability in patient response to treatment has become
an important limitation to immunotherapy. The difference in
tumor molecular landscape between patients provides the
rationale behind the differences in treatment response.
Recently, response to immunotherapy has been found to be
discordant between primary tumor and lymph node metastasis
in certain patients, illustrating the complexity of the immune
landscape in OCSCC (62). A study by Merlino et al. compared
treatment effect and radiographic volumetric response between
primary tumor and lymph node metastasis within the same

TABLE 2 | Biomarkers assessed in clinical trials using preoperative immunotherapy in advanced oral cavity squamous cell carcinoma.
Trial number

Patient population

Preoperative
immunotherapy

NCT02296684
(61)
NCT02919683
(66)

Stage III-IVb (AJCC,
7th ed) HPV- HNSCC
≥T2-4b or N+, M0
(AJCC, 7th ed)
OCSCC
Stage II-IVA OCSCC

Pembrolizumab

NCT03021993
(67, 68)
NCT02641093
(69)
NCT02274155
(70)
NCT03003637
(71)
NCT03129061
(72)

T3-4 and/or >2 +
LNs HPV- HNSCC
Stage III-IVa HNSCC
T3-4, N0-3, M0
HPV- HNSCC
Locally advanced
HNSCC

Nivolumab ±
ipilimumab

Biomarkers

PD-L1 IFNg pathway, immune and inﬂammatory genes (IFNG, CXCL9, CXCL10, CXCL11), T-cell checkpoint
molecules, (PDCD1, CTLA4, ICOS, TIGIT, IDO1, and TNFSF4), M1 macrophages CD4 and CD8 T cells
CD4+ T cells

Nivolumab

CD26, Tim

Pembrolizumab

PD-1, PD-L1, CD8+ T cells

Anti-Ox40
(MEDI6469)
Nivolumab ±
ipilimumab
Nivolumab vs
pembrolizumab

CD4+ T cells; CD103+ CD39+ CD8+ T cells

Frontiers in Oncology | www.frontiersin.org
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t u m o r g r o w t h (78 , 79) . I n s o l i d tu m o r s , r a t e s o f
pseudoprogression after immunotherapy is 10% (79). In
particular, the rate of pseudoprogression is exceedingly rare in
HNSCC (22, 23). KEYNOTE-012 and Checkmate-141, two trials
studying pembrolizumab and nivolumab, respectively, in
recurrent/metastatic HNSCC, reported 0.8% to 2.2% rate of
pseudoprogression. There has been sparse data on rates of
pseudoprogression after preoperative immunotherapy. An
aggressive form of progression, termed hyperprogression, has
also been identiﬁed and is characterized by an extremely rapid
rate of tumor growth and is associated with poor prognosis (80).
Similarly, hyperprogression is exceedingly rare after preoperative
immunotherapy, with single digit cases reported in the literature.
A phase II clinical trial (NCT03021993) studying preoperative
nivolumab in OCSCC (NCT03021993) described only 1 out of 9
patient with hyperprogression, who ultimately received deﬁnitive
surgery after the tumor doubled in size after immunotherapy
treatment (67).
Unfortunately, the development of an accurate measure to
distinguish pseudoprogression and true progression has proven to be
difﬁcult. Speciﬁc radiologic criteria have been developed to attempt
to identify pseudoprogression (81, 82). The deﬁnition of
hyperprogression has been variable in the literature and is based
on a combination of time to treatment failure and tumor kinetics
(80). Although rare in head and neck cancer, hyperprogression has
detrimental implications to the patient. The etiology behind
hyperprogression after immunotherapy has not been fully
elucidated and debate whether it is a result of the natural history
of an aggressive disease or poor response to immunotherapy is
ongoing. In the preoperative setting, hyperprogression can have
implications on the extent of surgical resection, subsequent
treatment, treatment response, and likely survival outcomes in few
patients. Thus far, there is no evidence that pseudoprogression or
hyperprogression has led to delays in deﬁnitive treatment (8). In the
context of a primary resectable OCSCC tumor, the rare occurrence
of hyperprogression after immunotherapy can potentially make a
resectable tumor unresectable, putting the patient at oncologic risk.
This raises the issue of tolerance of complications in the salvage
versus primary setting. In salvage treatment, the risk of oncological
demise justiﬁes certain complications from therapy. In the
potentially curable primary OCSCC, such limitations might not
be justiﬁed.

of a 4 week WOT supports the use of volumetric image analysis as
it relates to evidence of pathologic response (62). The difﬁculty
related to assessing tumor response has led to the advent of
metabolic imaging studies (72). Such studies rely on the
assumption that metabolic changes occur between radiographic
changes. A recent clinical trial (NCT03129061) used a PET
metabolic tracer ([18F]F-AraG), which preferentially accumulates
in activated CD8+ T cells, to assess response to anti-PD-1 therapy
(72). A patient with OCSCC had a 50% increase in [18F]F-AraG.
This was seen with a concurrent increase in intratumoral CD4+
and CD8+ cells, illustrating the correlation between results of this
new PET tracer and immune system activation. Additional clinical
indicators of favorable outcome include overall and disease-free
survival, which usually require large scale trials with long-term
follow up. Therefore, pathologic complete response (pCR) and
major pathologic response (MPR) were developed as markers of
favorable outcome. pCR refers to the absence of tumor cells in the
primary tumor site after surgical resection. Major pathologic
response refers to the presence of <10% of tumor cells within the
surgical specimen. Variations of pathologic response have also been
used in clinical trials; pathologic tumor response (pTR) categorizes
response into percentiles to include a wider range of response.
There is a correlation of radiographic response to pathologic
treatment response in head and neck cancer as early as 4 weeks
of treatment (62). Recently, multiple clinical trials have reported
favorable pathologic outcomes. A list of ongoing current trials,
which include patients with OCSCC receiving neoadjuvant
immunotherapy is presented in Supplemental Table 1. Initial
results were published as conference abstracts in 2018-2019. As
of 2020, multiple clinical trials have reported pathologic treatment
response results in scientiﬁc manuscripts. Most clinical trials are
not exclusive to OCSCC and include other HPV negative HNSCC.
Two trials have published results in OCSCC exclusively and have
reported favorable outcomes (66, 67). Clinical trials with reported
results in a manuscript or a conference presentation are presented
in Table 3. Here we discuss published scientiﬁc manuscripts
studying preoperative immunotherapy in OCSCC.

Preoperative Single Agent Immunotherapy
Most clinical trials in preoperative immunotherapy are investigating
the use of single agent immunotherapy in OCSCC. Five of the 8
clinical trials with published results have focused on single agent
immunotherapy. Of these 5 trials, 2 studied pembrolizumab, 2
studied nivolumab, and one studied the anti OX40
antibody, MEDI6469.
CHECKMATE 358 (NCT02488759) was the ﬁrst clinical trial
with published results presented in ESMO in 2017. Patients with
≥T1 and ≥N1 HNSCC were given 2 doses of nivolumab (240mg,
IV every 2 weeks). Twenty-nine patients were enrolled, 17 of
which had HPV negative tumors. Pathologic data has not been
reported yet. Grade 3/4 adverse events were recorded in 2/17
patients with HPV negative tumors. Reduction of tumor noted
by CT scan was seen in 6/13 of patients with HPV negative
tumors. Since the presentation of CHECKMATE358, WiseDraper et al. and Horton et al., have reported outcomes on
preoperative single agents pembrolizumab, and nivolumab,
respectively (67, 69). Favorable oncologic outcomes were

PREOPERATIVE IMMUNOTHERAPY
7WOT IN OCSCC
With the rapid development of the ﬁeld of preoperative
immunotherapy, surrogates of early success in clinical trials are
needed (58). There is a lack of consensus over which criteria best
indicates positive tumor response (83). The difﬁculty with using
imaging as a marker of tumor response is related to the
phenomenon of pseudoprogression described above. After
treatment, a radiographically detected mass can include both
tumor cells and inﬂammatory cells/debris. Our recent publication
correlating imaging with pathologic treatment effect in the context
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TABLE 3 | Results of published head and neck-speciﬁc clinical trials using preoperative immunotherapy.
Author

Trial Number Phase

Patient population

OCSCC

Preoperative therapy

Uppaluri et al. (61)

NCT02296684 II

Stage III-IVb (AJCC, 7th ed)
HPV- HNSCC (n = 36)

61%
(22/36)

Pembrolizumab (200mg)
13-22 days preoperatively

Schoenfeld et al. (66)

NCT02919683 II

≥T2-4b or N+, M0 (AJCC, 7th
ed) OCSCC (n = 29)

100%
(29/29)

Nivolumab (3mg/kg) wk 1
and 3 ± ipilimumab (1mg/
kg) wk 1; Surgery wk 4

Pathologic and safety
outcomes
pTR 10%–49% = 22%
pTR ≥ 50% = 22%
MPR > 90% = 6%
Grade 3-4 AE = 0%
Nivo (n=14)
pTR 10%–49% =
38%
pTR ≥ 50% = 15%
MPR > 90% = 8%
Grade 3-4 AE = 14%

Zinner et al. (73)

NCT03342911 II

Stage III/IVA (AJCC, 8th ed)
HPV- HNSCC (n=26)
Stage II/III (AJCC, 88h ed)
HPV+ OPSCC (n=6)

81%
(21/26)

Nivolumab (240mg) q 2
wks x 3
Carboplatin q wk x 6
Paclitaxel (100mg/m2) q
wk x 3
Nivolumab (3 mg/kg) q
2 weeks x 3/4

Horton et al. (67)

NCT03021993 II

Stage II-IVA OCSCC (n=9)

100%
(9/9)

Wise-Draper et al. (69)

NCT02641093 II

T3-4 and/or >2 + LNs HPVHNSCC (n=34)

Unknown

Pembrolizumab (200mg)
x1 1-3 wks preoperatively

Ferris et al. (84)
(CHECKMATE-358)

NCT02488759 I, II

≥T1 and ≥N1

Unknown

Nivolumab (240mg) q2
weeks x2

Bell et al. (MEDI6469)
(85)

Zuur et al. (IMCISION)
(71)

NCT02274155 Ib

NCT03003637 Ib/II

HPV+ (n=12)
HPV- (n=17)
HNSCC
Stage III-IVA
HPV+ (n=7)
HPV- (n=11)
HNSCC
T3-4, N0-3, M0 HPVHNSCC (n = 12)

Unknown

Anti OX40 antibody
(MEDI6469) (0.4mg/kg)
q2/3 days x3

Unknown

Nivolumab (240mg) wk 1
and 3 ± ipilimumab (1mg/
kg) wk 1
Surgery wk 5

Nivo + ipi (n=15)
pTR 10%–49% =
40%
pTR ≥ 50% =
33%
MPR > 90% =
20%
Grade 3-4 AE =
33%

HPV- HNSCC:
MPR > 90% = 65%
pCR = 42%
Grade 3-4 AE = 35%
pTR > 30% = 44%
pCR = 0%
Grade 3-4 AE = 0%
pTR ≥ 10% = 52%
pCR = 4%
Grade 3-4 AE = 3%
No pathologic data
Tumor reduction on CT scan = 48%
Tumor reduction 40 -75% = 13%
Grade 3-4 AE: HPV+ = 17%; HPV- = 12%
No pathologic data
Increased activation and proliferation of T
cells
Grade 3-4 AE = 0%
Nivo (n=6)
MPR >90% =
16.7%
pTR >50% = 0
Grade 3-4 AE =
16.7%

Niv + Ipi (n=6)
MPR >90% = 33.3%
pTR >50% = 16.7%
Grade 3-4 AE =
33.3%

AE, adverse events; AJCC, American Joint Committee on Cancer; HNSCC, head and neck squamous cell carcinoma; HPV, human papilloma virus; MPR; major pathologic response;
OCSCC, oral cavity squamous cell carcinoma; pCR, pathologic complete response; pTR, pathologic tumor response.

2 neoadjuvant doses (200mg, IV) 2 and 5 weeks preoperatively
instead of 1 and did not receive any adjuvant pembrolizumab.
The referenced manuscript highlights results from the ﬁrst arm
only. Primary endpoints included 1-year relapse rate in patients
with high-risk pathology and pTR. Thirty-six patients, 61% of
which had OCSCC, were enrolled in this trial. Pathologic
response was observed in 44% of the patients (22% of pts
with less than 10% pTR, 22% with 10-49% pTR). No patients
had complete pathologic response after one dose, which can be
related to monotherapy used in this trial, supporting the need
for combination therapy. Predictive biomarker discovery will
hopefully elucidate those that will beneﬁt from monotherapy vs
combinations. The one-year relapse rate amongst 18 patients
with high-risk pathologic features was 16.7% (95% CI, 3.6% –
41.4%), lower than the historical average (35%). Relapse-free
survival (RFS) in patients with >10% pTR was lower than

reported with low rate of grade 3/4 adverse events. The success of
these agents has led to clinical trials looking at different
immunotherapies. Bell et al., published preliminary safety
results on anti-OX40 antibody (MEDI6469) (85). There were
no grade 3/4 adverse events reported.
More recently, Uppaluri et al. published another study
focusing on use of neoadjuvant pembrolizumab (61). In this
multicenter, phase II trial NCT02296684 (MK-3475-689),
patients with surgically resectable stage III-IVb HPV negative
head and neck cancer were randomly assigned to 1 of 2 arms
(61). The ﬁrst arm received 1 dose of pembrolizumab (200mg,
IV) 13 to 22 days prior to deﬁnitive surgical resection. After
surgery, patients received standard of care adjuvant treatment
with the addition of pembrolizumab (200mg, IV, every 3 weeks
for 6 doses) in patients with high-risk pathology (positive
margins and extranodal extension). The second arm received
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Although the small sample size can be considered a limitation
in the above studies, the rate of pathologic response in patients
undergoing combination therapy is favorable compared to single
agent immunotherapy as noted in the IMCISION trial and the
above single agent trials. Nevertheless, as noted above,
combination immunotherapy increases risk of adverse events.
Therefore, although combination therapy can be effective, it
comes at the risk of a worse side effect proﬁle.

patients with no pTR (61). This result supports the correlation
between pathologic response and improved oncological
outcomes. Importantly, use of pembrolizumab was not
associated with any grade 3 or 4 adverse events or
unexpected delay in surgery. Although this study showed the
safety and lack of adverse events related to neoadjuvant
pembrolizumab the small number of patients (n=36) makes
drawing deﬁnitive conclusions difﬁcult. Outcomes of the 2nd
arm in this clinical trial will be vital in assessing the most
appropriate sequencing of immunotherapy (neoadjuvant
versus adjuvant) for oncologic success. An international
phase 3 trial is currently underway to evaluate the beneﬁt of
preoperative pembrolizumab in resectable, locally advanced
head and neck cancer (NCT03765918).

Preoperative Immunotherapy and
Chemotherapy
The value of combination therapy is not just limited to combination
immunotherapy but also combined with chemotherapy and
radiation. Out of the 8 currently published trials, only 1 looks at
combination immunotherapy and chemotherapy. In a phase 2 trial
(NCT03342911), patients with stage III-IVa HPV-negative head
and neck cancer received preoperative nivolumab (240mg IV every
2 weeks for 3 doses), paclitaxel (100mg/m2 IV once weekly for 3
weeks), and carboplatin (IV weekly for 6 weeks) before deﬁnitive
surgery (73). The primary endpoint was pCR at the primary site.
Twenty-six patients, 81% of which were OCSCC, were enrolled in
this study. This trial showed a favorable pathologic response with
rate of pCR and MPR being 11/26 (42%) and 17/26 (65%),
respectively. Importantly, this study highlights the effectiveness of
combination immunotherapy with other well-established therapies
(radiation therapy and chemotherapy) in the preoperative setting.
Grade 3/4 adverse events were seen in 9/26 (35%) of patients but
did not lead to delay of surgery. The higher toxicity rate in
combining immunotherapy, radiation, and chemotherapy once
again weighs against the oncological success of this therapy.
The promising results of preoperative immunotherapy have
opened an avenue for an abundance in clinical trials. As
highlighted above, combination checkpoint inhibitor therapy
has favorable outcomes but can have higher rates of toxicity.
This has led to the exploration of different methods of ﬁghting
the immunosuppressive environment in OCSCC. The
introduction of intratumoral therapies, oncolytic viruses, and
cancer vaccinations as tools to reinvigorate the immune system
provides insight on the future of immunotherapy in OCSCC.
This abundance of clinical trials aims to elucidate the molecular
mechanisms of pathologic response and its relationship to longterm oncological outcomes including survival and recurrence.
Although immunotherapy is an enticing new tool in
multidisciplinary management of OCSCC, the ﬁeld is still early
in its development and will require in-depth scientiﬁc
interrogation to solidify it as standard of care.

Preoperative Combination Immunotherapy
The favorable preliminary results seen in single agent preoperative
immunotherapy has led to an increase in number of clinical trials
with an interest in combination immunotherapy. Here we report
the results of 2 clinical trials studying combination
immunotherapy. The ﬁrst trial studying preoperative
combination immunotherapy was presented in ASCO in 2019
(71). The IMCISION trial (NCT03003637) was a phase 1b trial in
T3-4, N0-3, M0 HPV negative HNSCC patients. Twelve patients
were enrolled in this trial. Arm A received nivolumab (240mg IV)
weeks 1 and 3. Arm B received nivolumab weeks 1 and 3 and
ipilimumab (1mg/kg) week 1. Subsequently all patients received
surgery week 5 followed by standard of care adjuvant therapy. In
the 6 patients in Arm A, 1 patient had a near complete pathologic
response (>90% response) and 1 patient had grade 3/4 colitis. In
the 6 patients in Arm B, 3 patients had a pathologic response of
>50%, 2 of whom had a near complete pathologic response (>90%
response. Two patients had grade 3/4 adverse events, which
included 1 case of colitis and 1 case of hepatitis.
NCT02919683 published in 2020 highlighted the value of
combination therapy in preoperative OCSCC (66). In this phase
2 trial, OCSCC patients with T2-4b or node positive-disease with
no distant metastasis received 2 cycles of nivolumab (3mg/kg at
week 1 and 3 preoperatively) with or without ipilimumab (single
dose at 1mg/kg at week 1 preoperatively). Patients then
underwent surgery and received adjuvant therapy based on
standard of care. The measured endpoints were safety/
tolerability of the treatment and volumetric response (product
of longest perpendicular bidirectional tumor measurements).
Twenty-nine patients were enrolled (14 in nivolumab arm and
15 in nivolumab + ipilimumab arm). Volumetric response was
observed in 50% (80% CI, 30.5% – 69.5%) of nivolumab only
patients vs 53% (80% CI, 34.2% - 71.8%) in nivolumab +
ipilimumab patients. Speciﬁcally, 38% of patients in nivolumab
only arm vs 40% in nivolumab + ipilimumab arm had ≥ 10% and
<50% pTR, while 15% of patients in nivolumab only arm vs 33%
in nivolumab + ipilimumab had ≥ 50% pTR. Four patients had
major/complete pathologic response (>90%.); one (8%) patient
in the nivolumab alone arm and 3 (20%) patients in nivolumab +
ipilimumab cohort. Seven patients had grade 3/4 adverse events
including 2 grade 3/4 events in nivolumab only arm and 5 grade
3/4 events in nivolumab + ipilimumab arm.
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FUTURE PROSPECTS
Clinical trials have largely focused on monoclonal antibodies for
systemic delivery of immunotherapy in OCSCC. New
approaches such as cancer vaccinations and adoptive cell
transfer are under investigation (83).
Adoptive cell transfer includes harvesting T lymphocytes
from an autologous source, expanding them with IL-2,
identifying tumor-speciﬁc clones and reintroducing them to
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patients (86). Initial studies have shown success of adoptive cell
transfer in metastatic melanoma refractory to chemotherapy.
Patient response rate to adoptive cell transfer was reported at
56% in 93 patients with metastatic melanoma (87). Adoption of
cell therapy is in its early stages in HNSCC primarily used in
patients with recurrent/metastatic head and neck cancer. A phase
II clinical trial evaluating adoptive cell therapy with autologous
tumor inﬁltrating lymphocytes infusion followed by IL-2 for the
treatment of patients with recurrent and/or metastatic squamous
cell carcinoma of the head and neck is currently active
(NCT03083873). A recent study by Ohtani et al., reported a
40% response rate in 5 patients with stage IV HNSCC after a
mean follow-up of 26.2 months (88). Three patients received
adoptive cell therapy after no response to conventional
chemoradiation and 2 patients received therapy as adjuvant
treatment. Although an enticing new technology, the road to
adopting cell therapy in OCSCC, and speciﬁcally in the
preoperative setting, is still theoretic in nature.
Vaccinations can induce an active immune response by
presenting tumor antigens for T cell recognition and proliferation
(86). Vaccines can be 1) whole-protein vaccines, which mimic
tumor antigens and are subsequently presented to T cells, 2) wholecell vaccines, which carry a higher antigen burden and consist of
irradiated whole tumor cells, 3) autophagosome vaccines, which
recycle cellular components and cross-present them to T cells and
4) oncolytic virus vaccines, which causes tumor cell lysis and
subsequent presentation of tumor antigens to activate immune
system (86). The accessibility of oral cavity tumors has made
intratumoral delivery of vaccinations an attractive therapeutic
option. Vaccinations have been particularly attractive in patients
with HPV-related oropharyngeal squamous cell carcinoma due to
druggable oncoproteins E6 and E7. Multiple clinical trials
investigating the role of vaccines such as ISA-101 (targets E6 and
E7) and ADX 11-001 (targets E7) are underway in HPV-related
OPSCC (NCT02426892 and NCT02002182) with positive
preliminary results (89). The introduction of vaccines in the
OCSCC has lagged behind HPV-related oropharyngeal cancer. A
window of opportunity trial (NCT04247282) is currently
investigating the role of neoadjuvant TriAd vaccine along with
anti-PD-L1/TGF-beta Trap (M7824) and anti-IL15 in patients with
locally advanced, resectable stage II-IV HPV negative HNSCC. The
TriAd vaccine consists of three adenoviral vaccines, ETBX-051,
ETBX-061, ETBX-011, which target the 3 proteins, brachyury,
mucin-1, and carcinoembryogenic proteins respectively. The
primary endpoint is pathologic complete response after deﬁnitive
surgery. The results of this study may prove important for the
introduction of vaccinations in the preoperative setting of OCSCC.

speciﬁc needs. Multidisciplinary management of head and neck
cancer care has been shown to improve outcomes in head and
neck cancer (90). This is likely due to the wide array of specialists
bringing diverse knowledge and skills, improvement in
coordination and quality of care, decreased time to treatment,
and important focus on cancer survivorship (90). As such, the
National Comprehensive Cancer Network (NCCN), recommends
that patients be treated at high-volume centers with multidisciplinary
management and expertise (91).
The reinvigoration of immunotherapy has provided a
promising addition to the armamentarium in the ﬁght against
OCSCC while also adding another layer to its complexity. It is
important to acknowledge that immunotherapy is a developing
ﬁeld, and a signiﬁcant amount of information is yet to be
understood. Therefore, ongoing education with the latest
research is key as the ﬁeld is actively changing each day in
order to provide the most up-to-date evidence-based-care to
patients. Providers must be prepared to answer questions from
the patients who may have access to the latest research. On the
other hand, many patients may not be aware of these recent
breakthroughs in immunotherapy and opportunities to
participate in clinical trials allowing providers the opportunity
to participate in patient education.
As knowledge surrounding immunotherapy increases,
existing members of the multidisciplinary team will need to
tailor their care to include immunotherapy-speciﬁc issues. As we
continue to learn about the side effect proﬁle of immunotherapy,
a constant route of communication with the patient is essential in
order to recognize these events early to treat and prevent any
long-term harm to the patient. When these new adverse events
do arise, there should be prompt recognition and intervention
that may involve experts across different organ systems to
minimize poor outcomes. In patients undergoing preoperative
immunotherapy, coordination of care becomes of the utmost
importance to ensure the correct timing of immunotherapy
administration as it relates to surgery.

CONCLUSIONS
Current clinical trials are investigating a novel role for
immunotherapy as a method of treatment optimization in
OCSCC. Ultimately, the ﬁeld strives to improve oncologic,
safety, and functional outcomes in these patients. Preoperative
immunotherapy could provide an avenue both for treatment
intensiﬁcation (addition of systemic agents) and de-intensiﬁcation
(alteration of surgical approaches and subsequent adjuvant
therapy. At this time, these advantages are currently hypothetical
in nature. To truly achieve the goal of integrating immunotherapy
into the standard treatment paradigm, patient selection becomes
paramount. Current standards of treatment are deeply rooted in
TNM staging. WOT clinical trials in OCSCC strive to identify
predictive biomarker for patient selection and identiﬁcation of
targets for drug development (8). In the future we may have the
ability to risk stratify patients based on multiple factors including
pathology, response to preoperative immunotherapy, and immune
proﬁle to direct treatment (Figure 3). By generated individualized,

INTEGRATING IMMUNOTHERAPY INTO
MULTIDISCIPLINARY MANAGEMENT
As highlighted in the above sections, the complexity of head and
neck cancer starts at the molecular level and translates to the
clinical level. This provides rationale behind the need for
multidisciplinary management to provide optimal, patientcentered, individualized treatment that caters to patients’
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FIGURE 3 | Immune proﬁle of biopsied tumor can indicate need for preoperative immunotherapy in OCSCC. After deﬁnitive surgery, risk stratiﬁcation can be done
using pathologic data, immune proﬁle, and response to initial treatment. Level of risk can then dictate adjuvant therapy.

and approval. All authors contributed to the article and
approved the submitted version.

tumor-speciﬁc algorithms to achieve better oncologic and
functional outcomes we will one day be able to change the
treatment of OCSCC for the better.
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